Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Dillon R, Maycock S, Jackson A, Fox S, Freeman S, Craddock C, Thomas C, Homer E, Leahy J, Mamwell A, Potter N, Russell N, Wei A, Ommen HB, Hemmaway C, Knapper S, Billingham L. Dillon R, et al. Among authors: jackson a. BMC Cancer. 2022 Nov 14;22(1):1174. doi: 10.1186/s12885-022-10221-2. BMC Cancer. 2022. PMID: 36376888 Free PMC article.
The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.
Appleby N, Eyre TA, Cabes M, Jackson A, Boucher R, Yates F, Fox S, Rawstron A, Hillmen P, Schuh A. Appleby N, et al. Among authors: jackson a. BMC Cancer. 2019 May 20;19(1):471. doi: 10.1186/s12885-019-5717-y. BMC Cancer. 2019. PMID: 31109313 Free PMC article. Clinical Trial.
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, Andrew G, Nagra S, Malladi R, Peniket A, Gilleece M, Salim R, Tholouli E, Potter V, Crawley C, Wheatley K, Protheroe R, Vyas P, Hunter A, Parker A, Wilson K, Pavlu J, Byrne J, Dillon R, Khan N, McCarthy N, Freeman SD. Craddock C, et al. Among authors: jackson a. J Clin Oncol. 2021 Mar 1;39(7):768-778. doi: 10.1200/JCO.20.02308. Epub 2020 Dec 29. J Clin Oncol. 2021. PMID: 33373276 Free PMC article. Clinical Trial.
Reply to G. Gui et al.
Craddock C, Jackson A, Freeman SD. Craddock C, et al. Among authors: jackson a. J Clin Oncol. 2021 Jul 20;39(21):2416-2417. doi: 10.1200/JCO.21.00603. Epub 2021 May 5. J Clin Oncol. 2021. PMID: 33950696 No abstract available.
Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
Pascoe J, Jackson A, Gaskell C, Gaunt C, Thompson J, Billingham L, Steven N. Pascoe J, et al. Among authors: jackson a. BMC Cancer. 2021 Jul 12;21(1):800. doi: 10.1186/s12885-021-08519-8. BMC Cancer. 2021. PMID: 34247580 Free PMC article. Clinical Trial.
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial.
Malladi R, Ahmed I, McIlroy G, Dignan FL, Protheroe R, Jackson A, Moss P, Nunnick J, Siddique S, Bishop R, Elhaneid M, Hodgkinson A, Craddock C. Malladi R, et al. Among authors: jackson a. Bone Marrow Transplant. 2021 Dec;56(12):2948-2955. doi: 10.1038/s41409-021-01439-y. Epub 2021 Aug 26. Bone Marrow Transplant. 2021. PMID: 34446853 Clinical Trial.
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Chaganti S, Smith J, Chau I, Culligan D, Linton KM, Collins GP, Ferreri AJM, Lewis D, Davies AJ, Johnson R, Auer DP, Cwynarski K. Fox CP, et al. Blood Adv. 2021 Oct 26;5(20):4073-4082. doi: 10.1182/bloodadvances.2021004779. Blood Adv. 2021. PMID: 34464973 Free PMC article. Clinical Trial.
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Loke J, Metzner M, Boucher R, Jackson A, Hopkins L, Pavlu J, Tholouli E, Drummond M, Peniket A, Bishop R, Fox S, Vyas P, Craddock C. Loke J, et al. Among authors: jackson a. Br J Haematol. 2022 Jan;196(2):368-373. doi: 10.1111/bjh.17823. Epub 2021 Sep 6. Br J Haematol. 2022. PMID: 34490623 Free article.
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS.
Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J, Crawley C, Gilleece M, Peniket A, Protheroe R, Salim R, Tholouli E, Wilson K, Andrew G, Dillon R, Khan N, Potter V, Krishnamurthy P, Craddock C, Freeman S. Loke J, et al. Among authors: jackson a. Blood Adv. 2023 Jul 25;7(14):3666-3676. doi: 10.1182/bloodadvances.2022009493. Blood Adv. 2023. PMID: 37058448 Free PMC article.
5,193 results